Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
SARS-CoV-2 seroprevalence in pregnant women during the first three COVID-19 waves in The Gambia
International Journal of Infectious Diseases, Volume 135, Year 2023
Notification
URL copied to clipboard!
Description
Objectives: SARS-CoV-2 transmission in sub-Saharan Africa has probably been underestimated. Population-based seroprevalence studies are needed to determine the extent of transmission in the continent. Methods: Blood samples from a cohort of Gambian pregnant women were tested for SARS-CoV-2 total receptor binding domain (RBD) immunoglobulin (Ig) M/IgG before (Pre-pandemic: October-December 2019) and during the pandemic (Pre-wave 1: February-June 2020; Post-wave 1: October-December 2020, Post-wave 2: May-June 2021; and Post-wave 3: October-December 2021). Samples reactive for SARS-CoV-2 total RBD IgM/IgG were tested in specific S1- and nucleocapsid (NCP) IgG assays. Results: SARS-CoV-2 total RBD IgM/IgG seroprevalence was 0.9% 95% confidence interval (0.2, 4.9) in Pre-pandemic; 4.1% (1.4, 11.4) in Pre-wave 1; 31.1% (25.2, 37.7) in Post-wave 1; 62.5% (55.8, 68.8) in Post-wave 2 and 90.0% (85.1, 93.5) in Post-wave 3. S-protein IgG and NCP-protein IgG seroprevalence also increased at each Post-wave period. Although S-protein IgG and NCP-protein IgG seroprevalence was similar at Post-wave 1, S-protein IgG seroprevalence was higher at Post-wave 2 and Post-wave 3, (prevalence difference 13.5 [0.1, 26.8] and prevalence ratio 1.5 [1.0, 2.3] in Post-wave 2; and 22.9 [9.2, 36.6] and 1.4 [1.1, 1.8] in Post-wave 3 respectively, P <0.001). Conclusion: SARS-CoV-2 transmission in The Gambia during the first 3 COVID-19 waves was high, differing significantly from official numbers of COVID-19 cases reported. Our findings are important for policy makers in managing the near-endemic COVID-19. © 2023
Authors & Co-Authors
Janha, Ramatoulie E.
Gambia, Banjul
Medical Research Council Laboratories Gambia
Bah, Alasana
Gambia, Banjul
Medical Research Council Laboratories Gambia
Jah, Hawanatu
Gambia, Banjul
Medical Research Council Laboratories Gambia
Faye-Joof, Tisbeh
Gambia, Banjul
Medical Research Council Laboratories Gambia
Njie, Baboucarr
Gambia, Banjul
Medical Research Council Laboratories Gambia
Craik, Rachel
United Kingdom, London
King's College London
United Kingdom, Oxford
University of Oxford
Mohammed, Nuredin Ibrahim
Gambia, Banjul
Medical Research Council Laboratories Gambia
von Dadelszen, Peter
United Kingdom, London
King's College London
D'Alessandro, Umberto
Gambia, Banjul
Medical Research Council Laboratories Gambia
Roca, Anna
Gambia, Banjul
Medical Research Council Laboratories Gambia
Statistics
Authors: 10
Affiliations: 3
Identifiers
Doi:
10.1016/j.ijid.2023.08.012
ISSN:
12019712
Research Areas
Covid
Health System And Policy
Study Design
Cross Sectional Study
Cohort Study
Study Locations
Gambia
Participants Gender
Female